X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Ceftin concerns - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Ceftin concerns

May 23, 2002

Ranbaxy stock has been battered (down 9%) in the last couple of days. Besides, the general market pessimism what could be adding to the selling is the recent results declared by Lupin Labs. Ranbaxy currently is the sole generic marketer of Cefuroxime Axetil in the US markets. On the other hand, Lupin Labs has a contract to supply bulk required for Cefuroxime formulations to Apotex, who is the next competitor of Ranbaxy. It may be recalled that Ranbaxy received FDA approval for marketing Cefuroxime Axetil tablets in the US markets after a prolonged legal battle. Ceftum (generic Cefuroxime) is a molecule with a market size of US$ 400 m. Though the approval does not ensure six-month marketing exclusivity for Ranbaxy, the only generic competitor, Apotex is still in the process of getting the relevant FDA approval. Currently, it is awaiting US FDA approval and a final settlement of its lawsuit with GlaxoSmithkline.

Ranbaxy got the approval for Cefuroxime in Feb'02 and has already enjoyed almost 3 months of exclusivity. Even after Apotex approval (which we expect in July'02) the market is expected to be a duopoly atleast for a year after that. Ranbaxy has currently captured more than 50% market share for the drug with the generic drug priced at 30% discount to the branded Ceftin.

However, results of Lupin Labs for the fourth quarter show sales of Cefuroxime Axetil in the API form. This could be an indication that Apotex is soon expected to launch the drug in the US, breaking the generic monopoly status for Ranbaxy. However, the entry of competition from Apotex seems to be in line with our expectation of July launch. Further, as mentioned earlier it is unlikely that a third player would enter the market before mid 2003 and thus price cuts are not expected to be steep. We have factored in competition in our FY03 earnings expectations and we maintain our consolidated global EPS estimates of Rs 35 on the company. At the current market price of Rs 778, the stock trades at 22x consolidated global earnings for FY03.


Equitymaster requests your view! Post a comment on "Ranbaxy: Ceftin concerns". Click here!

  

More Views on News

THYROCARE TECHNOLOGIES Surges by 6%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

May 24, 2019 | Updated on May 24, 2019

THYROCARE TECHNOLOGIES share price has surged by 6% and its current market price is Rs 469. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are THYROCARE TECHNOLOGIES (up 5.7%) and FDC LTD. (up 7.0%). The top losers are FORTIS HEALTHCARE (down 0.1%) and GLENMARK PHARMA (down 0.7%).

NARAYANA HRUDAYALAYA LTD Surges by 7%; BSE HEALTHCARE Index Up 1.1% (Market Updates)

May 24, 2019 | Updated on May 24, 2019

NARAYANA HRUDAYALAYA LTD share price has surged by 7% and its current market price is Rs 200. The BSE HEALTHCARE is up by 1.1%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 6.8%) and FDC LTD. (up 7.3%). The top losers are JUBILANT LIFE SCIENCES (down 0.2%) and SHILPA MEDICARE (down 0.4%).

UNICHEM LAB Surges by 6%; BSE HEALTHCARE Index Up 1.1% (Market Updates)

May 24, 2019 | Updated on May 24, 2019

UNICHEM LAB share price has surged by 6% and its current market price is Rs 199. The BSE HEALTHCARE is up by 1.1%. The top gainers in the BSE HEALTHCARE Index are UNICHEM LAB (up 5.7%) and FDC LTD. (up 7.4%). The top losers are PFIZER (down 0.3%) and SHILPA MEDICARE (down 0.4%).

GRANULES INDIA Surges by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

May 24, 2019 | Updated on May 24, 2019

GRANULES INDIA share price has surged by 5% and its current market price is Rs 113. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is GRANULES INDIA (up 5.4%). The top losers are FORTIS HEALTHCARE (down 0.2%) and PFIZER (down 0.2%).

CAPLIN POINT Surges by 5%; BSE HEALTHCARE Index Up 0.8% (Market Updates)

May 24, 2019 | Updated on May 24, 2019

CAPLIN POINT share price has surged by 5% and its current market price is Rs 405. The BSE HEALTHCARE is up by 0.8%. The top gainers in the BSE HEALTHCARE Index is CAPLIN POINT (up 5.1%). The top losers are LAURUS LABS LTD (down 0.1%) and FORTIS HEALTHCARE (down 0.2%).

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


May 24, 2019 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS